In Vegfc-deficient embryos the differentiation of lymphatic endothelial cells from blood vascular endothelial cells in the cardinal veins appears unaffected, but they fail to egress from the cardinal veins. 2, 3 Compared with Vegfc-deficient embryos, the migration deficiency of nascent lymphatic endothelial cells in Ccbe1-deficient embryos is only partial. They form abnormal sprouts that fail to segregate from the cardinal veins, and the egressing lymphatic endothelial cells are unable to coalesce into discrete lymphatic structures. 3, 11 Hence, the earlier developmental block in the Vegfc-deficient embryos was attributed to the lack of a migration signal provided by VEGF-C, whereas the later block in Ccbe1-deficient embryos was attributed to a defect in endothelial cell migration, perhaps because of the lack of migratory cues from the extracellular matrix, of which CCBE1 is thought to be a component. 12 Both Ccbe1+/− and Vegfc+/− heterozygous embryos show a reduction of Prox1-positive endothelial cells emigrating from the cardinal veins. 3 The double heterozygous Ccbe1+/−;Vegfc+/− embryos have an aggravated version of this phenotype, suggesting that CCBE1 and VEGF-C participate synergistically in the lymphatic separation, 3 which is also supported by data from zebrafish. 12 In the present study, we have explored the link between CCBE1 and VEGF-C using both in vitro and in vivo assays and report that CCBE1 affects lymphangiogenesis by enhancing the cleavage of VEGF-C by the A disintegrin and metalloprotease with thrombospondin motifs-3 (ADAMTS3) metalloprotease, which removes the N-terminal propeptide from pro-VEGF-C, resulting in the mature, fully active VEGF-C.
Methods

Transfections, Metabolic Labeling, and Protein Analysis
293T and 293S GnTI − cells were (co)transfected with expression constructs coding for the indicated proteins. Twenty-four hours after the transfection, the cells were metabolically labeled with [ 35 S]-cysteine/ [
35 S]-methionine (PerkinElmer, Waltham, MA), and 48 hours later, conditioned cell culture medium and lysates were harvested. For the short-term labeling experiments, harvesting was performed after 24 hours. To produce unlabeled protein, the culture media were exchanged and supernatants and lysates harvested 48 hours later. After immunoprecipitation, the samples were electrophorated in 4% to 20% SDS-PAGE. For autoradiography, gels were dried and exposed to phosphoimager plates or x-ray film. For the immunodetection, the proteins were transferred to nitrocellulose. Specific signals were detected by enhanced chemiluminescence. Quantitation of the autoradiographies and Western blots was performed from the laser scanner readouts or scanned x-ray film using the ImageJ software (National Institutes of Health, Bethesda, MD).
Ba/F3-VEGFR/EpoR Assays
The Ba/F3-hVEGFR-3/EpoR, 13 Ba/F3-mVEGFR-2/EpoR 14 and Ba/ F3-hVEGFR-2/EpoR bioassays were performed with conditioned cell culture medium as described. 15 
Stimulation of VEGFR-3 Phosphorylation
Near confluence porcine aortic endothelial cells expressing VEGFR-3 or VEGFR-3 plus neuropilin-2 were washed with PBS and starved over night in DMEM 0.2% BSA. ΔNΔC-VEGF-C, pro-VEGF-C, and CCBE1Δ175 were diluted to 0.02, 0.40, and 5.00 μg/mL in 1 mL of DMEM/0.1% BSA and incubated at 37°C for 30 minutes. The cells were stimulated for 10 or 30 minutes to detect phosphorylation of VEGFR-3 or downstream signaling proteins and then washed with ice-cold PBS. To cross-link proteins, the cells were washed twice with PBS, and purified proteins were applied in PBS (ΔNΔC-VEGF-C 100 ng/mL, pro-VEGF-C 1000 ng/mL, and CCBE1Δ175 at 25-50 μg/mL). After 3.5 minutes DTSSP (ThermoScientific, Waltham, MA) was added to a final concentration of 2 mmol/L, and cross-linking was performed for 6.5 minutes at 37°C. Cells were washed once with ice-cold TBS, lysed with 1% Triton X-100, and the immunoprecipitated fraction or the total lysate analyzed by SDS-PAGE/Western blot.
VEGFR-3 Trafficking in Human Umbilical Vein Endothelial Cells
Human umbilical vein endothelial cells stably transfected with the pMXs-VEGFR-3-green fluorescent protein vector 16 were grown on glass-bottom microwells (MatTek Co, Ashland, MA) for 24 hours. The FCS concentration was reduced to 0.5%, and 12 hours thereafter, the cells were placed in an incubator (36°C and 5% CO 2 ) on a Zeiss LSM 5 DUO Confocal microscope and treated with pro-VEGF-C or ΔNΔC-VEGF-C (100 ng/mL). The green fluorescent protein signal was recorded at the 488-nm wavelength. The human VEGFR-3 blocking antibody hF4-3C5 was used at 5 μg/mL.
Recombinant Adeno-Associated Viral Vector Production
Adeno-associated viral vector (AAV) 9 vectors were made by a 3-plasmid transfection method and purified by ultracentrifugation using discontinuous iodixanol gradient, as described, 17 except that we used the serotype-determining helper plasmid p5E18-VP2/9 instead of p5E18-VP2/8.
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In Vivo Experiments
Tibialis anterior muscles of FVB/N male mice were injected with 1:1 mixed solutions of AAV9s encoding mouse (m)CCBE1-V5, mVEGF-C, or HSA. The AAV9-HSA and AAV9-ΔNΔC-mVEGF-C single vectors were used as negative and positive controls, correspondingly. The total concentration of the vector particles in a single injected dose was 6×10 10 . Three weeks after transduction, the mice were euthanized by CO 2 overdose. The tibialis anterior muscles were isolated, embedded into O.C.T. (Sakura Finetek Europe, Alphen aan den Rijn, The Netherlands), sectioned (10-μm thickness), and stained for the lymphatic (Lyve-1, Prox-1) and blood vascular markers (platelet endothelial cell adhesion molecule-1), as well as smooth muscle cell/pericyte (smooth muscle actin) and leukocyte (CD45) markers, followed by Alexa-conjugated secondary antibodies (Molecular Probes, Invitrogen, Life Technologies, Carlsbad, CA). Fluorescent images were obtained in an Axioplan microscope (Carl Zeiss AG, Oberkochen, Germany); the objectives were as follows: 10× numerical aperture = 0.3 and working distance = 5.6 mm and 20× numerical aperture = 0.5 and working distance = 2.0 mm; the camera was a Zeiss AxioCamHRm 14-bit greyscale charge-coupled device; the acquisition software was Zeiss AxioVision 4.6. Quantification of the areas stained for Lyve-1, platelet endothelial cell adhesion molecule-1, and smooth muscle actin was done as described previously. 17 Shortly, we used the ImageJ software measuring the percentage of pixels that showed values above background in the appropriate color channel using the "measure" function. Prox-1 positive nuclei were counted manually. The detection of luciferase activity in EGFP/Luc Vegfr3 EGFP/Luc mice was performed as described previously. 19 The National Board for Animal Experiments of the Provincial State Office of Southern Finland approved all of the animal experiments carried out in this study.
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Statistical Analysis
Significance of the differences was determined using 1-way ANOVA. 
Results
CCBE1 Enhances VEGF-C Processing and Release, Resulting in Increased VEGFR-3 Activation
CCBE1 was detected as a protein of 40 to 55 kDa molecular weight in both cell lysates and conditioned media of 293T cells transfected with a CCBE1 expression vector ( Figure 1A ). 20 However, most of the secreted CCBE1 migrated as a diffuse band of ≈100 kDa. Transfected VEGF-C was expressed as the uncleaved 58 kDa precursor, C-terminally processed 29/31 kDa the pro-VEGF-C form, and fully processed 21 kDa the mature form ( Figure 1B , lane 1). 4, 21 However, when VEGF-C and CCBE1 were cotransfected, the amounts of the unprocessed VEGF-C and pro-VEGF-C were reduced, and the mature, fully activated VEGF-C became the major species ( Figure 1B Conditioned medium from the CCBE1/VEGF-C cotransfected cultures stimulated the growth and survival of Ba/ F3-VEGFR-3/EpoR and Ba/F3-VEGFR-2/EpoR cells better than the medium of cells transfected with VEGF-C alone, whereas medium from CCBE1 transfected cells alone showed very little activity, indicating that the enhanced release and cleavage resulted in increased levels of active VEGF-C ( Figure 1C and Figure IC in the online-only Data Supplement). Notably, CCBE1 also slightly promoted the survival of Ba/F3-VEGFR-3/EpoR cells, presumably because of increased processing and activation of endogenous VEGF-C made by the cells.
CCBE1 Enhances VEGF-C Processing In Trans
In the developing mouse and zebrafish embryo, CCBE1 is expressed in cells adjacent to developing lymphatic vessels. 3, 12 We thus determined whether CCBE1 production in trans by other cells also enhances VEGF-C processing. We transfected separate cultures of 293T cells with VEGF-C or CCBE1 and mixed the cell populations 24 hours after transfection. Alternatively, we mixed CCBE1-transfected cells with cells stably expressing VEGF-C. In these experiments, CCBE1 increased the efficiency of the extracellular processing of VEGF-C but not its release ( Figure ID in the onlineonly Data Supplement).
CCBE1 Enhances the Lymphangiogenic Activity of VEGF-C In Vivo
Proteolytic processing of VEGF-C has been shown to increase its receptor affinity and biological activity. 4, 17 To investigate whether CCBE1 enhances VEGF-C-induced lymphangiogenesis in vivo, we transduced mouse tibialis anterior muscles with AAV9 expressing CCBE1 (AAV9-CCBE1) alone or together with AAV9-VEGF-C in a 1:1 ratio or AAV9-HSA as a negative control. AAV9 encoding the mature, activated form of VEGF-C (∆N∆C-VEGF-C) was used as a positive control.
Three weeks after the AAV transduction, the muscles were analyzed by immunohistochemistry using markers for endothelial cells (platelet endothelial cell adhesion molecule-1), lymphatic endothelial cells (lymphatic vessel endothelial hyaluronan receptor (Lyve)-1, Prox1), and leukocytes (CD45). In this assay, both VEGF-C and ∆N∆C-VEGF-C stimulated lymphangiogenesis. ∆N∆C-VEGF-C gave a considerably stronger response at the same viral dose and stimulated additionally angiogenesis (Figure 2 and Figure II in the online-only Data Supplement, bottom row). This suggested that the proteolytic processing of VEGF-C was inefficient in the AAV9-transduced muscle.
However, when VEGF-C was cotransduced with CCBE1, lymphangiogenesis was significantly enhanced, as shown by the Lyve-1 and Prox-1 staining (Figure 2 ). Similar to the ∆N∆C-VEGF-C transduced muscle, significantly more angiogenesis and leukocyte recruitment were observed (Figures II and III in the online-only Data Supplement). These results indicated that CCBE1 enhances VEGF-C processing also in vivo.
To corroborate these findings, we used the AAV9s encoding the various VEGF-C forms and CCBE1 in mice heterozygous for a Vegfr3 EGFP/Luc allele to monitor lymphangiogenesis by optical bioluminescent imaging in vivo. 19 We detected strong luciferase signals in mice cotransduced with the AAVs encoding VEGF-C and CCBE1, weaker signals in mice transduced with VEGF-C or CCBE1 alone, and no bioluminescent signals in mice transduced with HSA ( Figure 3 ).
VEGF-C and CCBE1 Are Processed by the ADAMTS3 Procollagenase
Our attempts to demonstrate a physical interaction of VEGF-C and CCBE1 were unsuccessful ( Figure IVA in the online-only Data Supplement). We thus assumed that the CCBE1-VEGF-C interaction is short lived and/or indirect, perhaps mediated by the protease that removes the N-terminal propeptide of VEGF-C. We stably expressed CCBE1 in 293T cells, purified the protein, and subjected it to tryptic digestion followed by mass spectrometry. The most abundant copurified protease was ADAMTS3. Efficient N-terminal processing of pro-VEGF-C was obtained when ADAMTS3 was expressed together with VEGF-C in 293T cells ( Figure 4A ). To analyze whether CCBE1 enhances the ADAMTS3-mediated VEGF-C cleavage, the amounts of ADAMTS3 used for VEGF-C cleavage were titrated. When CCBE1-, VEGF-C-, and ADAMTS3-conditioned media were mixed in a ratio of 60:30:1, the ADAMTS3-mediated cleavage of VEGF-C was more efficient in the presence of CCBE1 than without ( Figure 4B ), and a corresponding medium had growth-promoting activity in the VEGFR-3/ EpoR-expressing Ba/F3 cells ( Figure 4C ). When the culture media of the ADAMTS3 cotransfected samples were precipitated with ADAMTS3 antibodies or streptactin and analyzed in Western blotting with antibodies recognizing the C-terminus of CCBE1, the specific CCBE1 band migrated at 25 kDa, which corresponds to the collagen-like domain of CCBE1 ( Figure 4D ), indicating that ADAMTS3 may cleave CCBE1 between the epidermal growth factor and collagen homology domain. Interestingly, the DU-4475 cells produced only uncleaved CCBE1 ( Figure IVB 
ADAMTS3 Produced by 293T Cells Processes VEGF-C to the Mature Form
The N-terminus of the mature VEGF-C generated by incubation with recombinant, purified ADAMTS3 was identical to that reported for mature VEGF-C produced by 293 cells Apart from ADAMTS3, 2 other proteases, ADAMTS2 and ADAMTS14, belong to the procollagenase subfamily of ADAMTS proteases. 24 Interestingly, the ADAMTS1 gene deletion in mice results in deficient ovarian lymphangiogenesis. 25 However, unlike ADAMTS3, ADAMTS1, 2, or 14 did not cleave VEGF-C ( Figure VID in the online-only Data Supplement).
We found that the cell lines that produce active, mature VEGF-C (293T, 293T-CCBE1, and PC-3 cells) express ADAMTS3, whereas the cell lines that were unable or extremely inefficient in producing active VEGF-C (CHO and NIH-3T3), expressed very little or no ADAMTS3 ( Figure  VII in the online-only Data Supplement). Furthermore, when ADAMTS3 was silenced in 293T cells by using lentiviral short-hairpin RNA, the VEGF-C cleavage was inhibited (Figure VIIIA in the online-only Data Supplement).
VEGF-C/VEGF-D chimeras generated by propeptide swapping were not subject to ADAMTS3 cleavage ( Figure  VIIIB and VIIIC in the online-only Data Supplement). Interestingly, however, 79% of VEGF-C processing was inhibited by the purified C-terminal propeptide and 43% by the N-terminal propeptide, whereas the VEGF homology domain or HSA gave no inhibition ( Figure VIIID) , suggesting that the VEGF-C propeptides are necessary but not sufficient for VEGF-C recognition by ADAMTS3.
The N-Terminal Domain of CCBE1 Enhances Pro-VEGF-C Cleavage to the Mature Form
Because of the difficulty in expressing sufficient amounts of full-length CCBE1, we investigated whether the isolated N-terminal domain of CCBE1 (CCBE1Δ175) can increase VEGF-C activity. We stimulated VEGFR-3-transfected porcine aortic endothelial cells with pro-VEGF-C, which resulted in very little VEGFR-3 phosphorylation when compared with mature VEGF-C ( Figure 5A, lanes 1 and  2) . When the recombinant CCBE1Δ175 was added to pro-VEGF-C, VEGFR-3 phosphorylation was strongly increased ( Figure 5A, lane 3) . Analysis of VEGFR-3 coprecipitated proteins from the pro-VEGF-C stimulated cells indicated that both pro-VEGF-C and mature VEGF-C are bound to the receptor in the presence of CCBE1Δ175 ( Figure 5B, compare lanes 2 and 3) . To identify which form of VEGF-C was bound to the phosphorylated VEGFR-3 receptor, we applied purified CCBE1Δ175 and biotinylated, purified pro-VEGF-C to cultures of porcine aortic endothelial-VEGFR-3 cells in PBS for 210 seconds and crosslinked VEGFR-3-associated proteins for 390 seconds. Precipitation and analysis of tyrosyl phosphorylated proteins indicated that mature VEGF-C is bound to activated VEGFR-3 when both CCBE1Δ175 and pro-VEGF-C are used for the stimulation ( Figure 5C ). Pro-VEGF-C alone did not coprecipitate with VEGFR-3, unless VEGFR-3 was coexpressed with the VEGF-C coreceptor neuropilin-2 ( Figure 5D) . However, even then, pro-VEGF-C induced very little phosphorylation of VEGFR-3 (data not shown).
Pro-VEGF-C Can Act as a Competitive Inhibitor of Mature VEGF-C
We next analyzed the ability of pro-VEGF-C to inhibit VEGFR-3 activation by mature VEGF-C. Indeed, preincubation of lymphatic endothelial cells with high amounts of pro-VEGF-C inhibited their ability to respond to mature VEGF-C ( Figure 6A ). Unlike mature VEGF-C, pro-VEGF-C did not stimulate the endocytosis of VEGFR-3 or the phosphorylation of the Erk, Akt, or endothelial NO synthase downstream signaling proteins in blood vascular endothelial cells or lymphatic endothelial cells ( Figure 6B and 6C).
Discussion
CCBE1 is essential for embryonic lymphangiogenesis. [10] [11] [12] However, it has been unclear how it controls the lymphangiogenic response. Here we show that CCBE1 acts by regulating the cleavage of pro-VEGF-C into its active form. During its biosynthesis, unprocessed VEGF-C first undergoes a cleavage in the C-terminal part, resulting in pro-VEGF-C, and subsequently in the N-terminal part, yielding the mature form of VEGF-C. 4 Proprotein convertases such as furin mediate the C-terminal cleavage of VEGF-C, 26 but the protease that cleaves the N-terminal propeptide has not been clearly defined. We show that, whereas CCBE1 does not cleave VEGF-C, it greatly enhances the ADAMTS3-mediated N-terminal cleavage and activation of pro-VEGF-C. The N-terminal cleavage process seems inefficient in the majority of cultured cell lines, thus little of the pro-VEGF-C gets activated. Because of the remarkable difference in the lymphangiogenic potential between pro-VEGF-C and mature VEGF-C, 17 it has been assumed that, analogous to VEGF-A, 27 ,28 the proteolytic environment would be a critical determinant controlling VEGF-C bioavailability and activity in vivo. 4, 29 Our data indicate that CCBE1 expression in tissues could regulate VEGF-C activation in the lymphatic endothelial microenvironment in a spatially controlled manner.
We were unable to demonstrate a direct interaction between CCBE1 and VEGF-C, but CCBE1 interacted with the metalloproteinase ADAMTS3, as shown by mass spectrometry and a functional assay. ADAMTS3 cleavage of pro-VEGF-C was enhanced by CCBE1, whereas plasmin cleavage was not. The expression pattern of ADAMTS3 makes it a more likely candidate for VEGF-C activation during embryonic lymphangiogenesis than plasmin, 30, 31 but in wound healing and other invasive processes, where plasminogen becomes activated, VEGF-C activation (and deactivation) may occur via plasmin. May 13, 2014
Although pro-VEGF-C is known to bind to VEGFR-3, 4,32,33 it did not bind to or activate VEGFR-3 on its own in the porcine aortic endothelial-VEGFR-3 cells. However, when we introduced neuropilin-2, we could establish binding, yet we detected very little VEGFR-3 phosphorylation. This explains the competitive inhibition of mature VEGF-C activity by pro-VEGF-C in lymphatic endothelial cells, which express neuropilin-2.
34,35
When we applied pro-VEGF-C with CCBE1 and cross-linked proteins that were bound to activated VEGFR-3, we detected mature VEGF-C. Thus, a rapid CCBE1-assisted cleavage of receptor-bound pro-VEGF-C by a cell-surfaceassociated protease appears responsible for the CCBE1 enhancement of pro-VEGF-C signaling activity. This is consistent with the fact that only little of the cleavage activity is released into the medium. The demonstration of CCBE1 enhancement in conditioned cell culture supernatants required carefully titrated amounts of ADAMTS3, pro-VEGF-C, and CCBE1, whereas the CCBE1 enhancement during the short VEGFR-3 phosphorylation period of 10 minutes was robust. Endothelial cells express ADAMTS3, 36 most of which likely remains cell surface-associated because of its thrombospondin motif, which contains the high-affinity SVTCG binding site for CD36. 37 We propose the model of VEGFR-3 activation shown in Figure 7 . First, CCBE1 enables pro-VEGF-C binding to VEGFR-3. After binding, pro-VEGF-C becomes a substrate for proteases such as ADAMTS3, and the resulting in situ-generated mature VEGF-C initiates signaling. Such in situ activation of pro-VEGF-C could contribute to the lack of blood vascular effects of VEGF-C in some in vivo models, 38 despite the ability of mature VEGF-C to activate VEGFR-2. The generation of mature VEGF-C also occurred in the culture medium, albeit much less efficiently. This could explain the modest angiogenesis that accompanied the prominent lymphangiogenic effect in vivo. in some instances, the angiogenic effect may be mediated via VEGFR-3.
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CCBE1 expression is spatially and temporally correlated with the migration routes of endothelial cells that bud from the cardinal veins. 3, 12 We could detect low amounts of CCBE1 in most cultured cell lines tested. Perhaps matrix association of CCBE1 via vitronectin 11 could lead to high local CCBE1 concentrations, focusing ADAMTS3 activity to areas where VEGF-C activity is needed, for example, at sites where nascent lymphatic endothelial cells emigrate from the venous compartment. This resembles the concentration of plasminogen activator activity by vitronectin to cell surfaces and the extracellular matrix by binding to the urokinase-type plasminogen activator/soluble urokinase-type plasminogen activator receptor complex. 42 VEGF-D, which is the closest homolog of VEGF-C, 43, 44 was not cleaved by ADAMTS3, and CCBE1 did not have any effect on its activation. Alignment of VEGF-C and VEGF-D orthologs reveals that both contain multiple potential plasmin cleavage sites in the linker connecting the N-terminal propeptide with the VEGF homology domain ( Figure VIC in the online-only Data Supplement). Preferential cleavage at one site over the other might explain why limited exposure to plasmin activates VEGF-C, whereas longer exposure results in VEGF-C inactivation. The net charge of the polypeptide segment between the first potential plasmin cleavage site and the ADAMTS3 cleavage site in VEGF-C is very different from that in VEGF-D. This could explain the differential action of both plasmin and ADAMTS3 on these substrates despite similar cleavage motifs.
The cleavage motif of ADAMTS3 in VEGF-C is the same as the ADAMTS2 motif in procollagens (FA[AP]↓), 45 which have been until now the only known substrates of ADAMTS3. 46 This motif is also found in bone morphogenetic protein-2 and pleiotrophin. ADAMTS3 cleavage likely requires additional interactions, because exogenously added C-terminal VEGF-C propeptide and, to a lesser extent, also the N-terminal propeptide were able to compete with the cleavage. Surprisingly, a CCBE1 cleavage product appeared in the supernatants of ADAMTS3-transfected cells, although CCBE1 lacks the FA[AP]↓ motif. The cleavage of CCBE1 into 2 separate domains may be a prerequisite for its activity, because the inability of the conditioned medium of the DU-4475 cell line to activate pro-VEGF-C was associated with a lack of CCBE1 cleavage products.
In addition to the cleavage by ADAMTS3, CCBE1 also accelerated the release of VEGF-C. Although the C-terminal cleavage is not a prerequisite for secretion, 26 the presence of the C-terminal propeptide slowed VEGF-C release compared with truncated VEGF-C forms lacking this propeptide in metabolic labeling pulse-chase experiments, indicating that facilitation of the C-terminal processing may be responsible for the enhanced release. However, the relevance of this finding is not yet clear, because it is uncertain whether cells that express both CCBE1 and VEGF-C exist in vivo.
On the basis of our findings, the lymphatic vessel defects seen in animal models lacking CCBE1 can be explained, because CCBE1 appears essential for VEGF-C activation. Furthermore, a decrease of CCBE1 expression together with other lymphangiogenic genes in the postnatal period in some tissues (Jeltsch et al, unpublished data, 2014 ) and potential additional substrates of ADAMTS3 suggest that CCBE1 also has lymphangiogenesis-independent roles, which may explain some of the other features of Hennekam lymphangiectasialymphedema syndrome. 8, 47 Finally, as shown by the in vivo data, CCBE1 may offer a useful target for the modulation of VEGF-C activity, which could be used for therapeutic stimulation and inhibition of lymphangiogenesis and perhaps also angiogenesis. 48 
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CLINICAL PERSPECTIVE
There has been substantial progress in the understanding of the hereditary lymphedemas. However, the molecular mechanism is not always obvious, even when the genetic lesion has been identified. In 2009, Alders et al established the link between mutations in the CCBE1 gene and Hennekam lymphangiectasia-lymphedema syndrome, a human hereditary condition with lymphedema as a characteristic feature. Later, genetic experiments in zebrafish and mice indicated that the CCBE1 gene interacts with the lymphangiogenic vascular endothelial growth factor (VEGF)-C receptor-3 pathway, but the nature of the interaction remained elusive. In this article, Jeltsch et al show that the activity of VEGF-C is regulated by collagen-and calcium-binding epidermal growth factor domains 1 (CCBE1), which facilitates the proteolytic activation of a latent "pro" form of VEGF-C by the A disintegrin and metalloprotease with thrombospondin motifs-3 (ADAMTS3) metalloproteinase via a novel mode of growth factor activation. The in vivo data in the article show that CCBE1 is a potential therapeutic tool for the modulation of lymphangiogenesis and angiogenesis in a variety of diseases that involve the lymphatic system, such as lymphedema or lymphatic metastasis. In particular, application of VEGF-C has been scheduled for clinical trials to improve the incorporation of lymph node transplants into the lymphatic vascular system after mastectomy and axillary lymph node surgery. CCBE1 is a powerful activator of VEGF-C that can facilitate therapeutic lymphangiogenesis. CCBE1 and ADAMTS3 could also provide new targets for inhibition of tumor angiogenesis, lymphangiogenesis, and metastasis.
Supplemental Material Supplemental Methods
Cloning. Genes expressed via the recombinant adeno-associated virus (AAV9) vector were cloned into the psubCAG-WPRE plasmid 1 , which is a derivative of psubCMV-WPRE, where the CMV promoter has been replaced with the composite CAG promoter (consisting of the chicken β-actin promoter, cytomegalovirus enhancer and β-actin intron 2 ). Cloning of fulllength mVEGF-C, ΔNΔC-mVEGF-C and HSA into AAV-vector (psubCAG-WPRE) was described earlier 3 . mCCBE1, fused to a V5 tag (mCCBE1- the Ba/F3 cells. Cells were grown in medium containing 2 ng/ml mIL-3 for 36 hours, after which they were split and selection was started for three weeks with 1.2 mg/ml G418. Cells were maintained with sub-optimal mIL-3 concentration (0.4 ng/ml) and optimal VEGF-A and VEGF-C concentrations (200 and 300 ng/ml, respectively).
Protein expression and purification. S2 cells were transfected using Effectene (Qiagen, Venlo, The Netherlands). Stable cell pools were selected for 3 weeks with 400 µg/ml hygromycin starting 2 days after transfection. For protein production, the cells were adapted to suspension culture and induced for 4-5 days with 1 mM CuSO 4 . After batch-binding to Ni 2+ NTA sepharose from the pH-adjusted conditioned supernatant, the Ni 2+ NTA sepharose was loaded onto a column, washed with 20 mM imidazole, and eluted with a step-gradient of 250 mM imidazole. The protein was further size-separated on a Superdex 200 column with PBS as a running buffer.
Recombinant baculovirus was produced using the FactBac system (Invitrogen, Carlsbad, CA)
according to the instructions of the manufacturer. Sf9 cells were infected and conditioned medium harvested 4 days post infection. Protein purification was performed as above.
CCBE1Δ175 was purified in Hepes-buffered saline supplemented with 2 mM CaCl 2 .
CCBE1 was enriched from 200 ml conditioned medium of 293T cells expressing StrepIIItagged CCBE1 using streptactin sepharose (IBA) according to the instructions of the manufacturer, and the eluted peak fraction was dialyzed against TBS. Histidine-tagged ADAMTS3 was purified from 1.5 litres of conditioned medium of stably transfected 293F cells (D-MEM supplemented with 2%FCS, 30µM ZnCl 2 and 0.1U heparin/ml). The collected medium was dialyzed against phosphate buffered saline, pH-adjusted to 8.0 and batch-bound protein was eluted with a step-gradient of 250 mM imidazole from the Ni 2+ NTA sepharose (IBA) after washing with 20 mM imidazole and dialyzed against 1xTBS. Biotinylated ∆N∆C-VEGF-C and pro-VEGF-C were generated from purified proteins using sulfosuccinimidyl-6- Mass spectroscopy. Enriched CCBE1 protein was subjected to liquid chromatography-mass spectrometry as previously described 16 . In short, mass spectrometry analysis was performed on an Orbitrap Elite ETD mass spectrometer (Thermo Scientific) using the Xcalibur version 2.7.1 coupled to a nLCII nanoflow system (Thermo Scientific) via a nanoelectrospray ion source. Peak extraction and subsequent protein identification was achieved using Proteome
Discoverer software (Thermo Scientific). Calibrated peak files were searched against human protein databases by the SEQUEST search engine. Database searches were limited to tryptic peptides with a maximum of 1 missed cleavage; carbamidomethyl cysteine and methionine oxidation were set as fixed and variable modifications, respectively. Quantitative PCR for ADAMTS2, -3 and -14. Total RNA was isolated from the cells with NucleoSpin RNA II kit according to the protocol (Macherey-Nagel, Düren, Germany) and cDNA synthesis was performed using iScript cDNA synthase kit (Bio-Rad; Hercules, CA).
QPCR was carried out using SYBR green chemistry with Bio-Rad CFX96 Real-Time System.
All data were normalized to GAPDH and quantification was performed using the 2-DDCT method. The following primers were used: hADAMTS2 ( )   ADAMTS 2  14  3  2  14  3  2  14  3  2  14  3  2  14  3   ADAMTS2 ADAMTS3 ADAMTS14 
